Aimovig Market Report 2026

Aimovig Market Overview

• The Aimovig market growth in the historic period has been driven by high migraine prevalence, limited effectiveness of traditional therapies • Market expansion is supported by growth in chronic migraine diagnosis, expansion of insurance coverage • Growth Driver: Rising Migraine Incidence Fuels Growth Of Aimovig Market • North America was the largest region in 2025.

What Is Covered Under Aimovig Market?

Aimovig is a therapy designed to prevent migraines by targeting the calcitonin gene-related peptide (CGRP) receptor. It works by blocking CGRP activity, a protein that contributes to the occurrence of migraines, thereby reducing their frequency and severity. The main clinical indication for aimovig is migraine, cluster headache, other headache disorders. A migraine is a type of primary headache disorder characterized by recurrent, often severe, headaches that are typically one-sided (though they can affect both sides), and are often accompanied by other symptoms such as nausea, vomiting, and sensitivity to light, sound, or smells. These are distributed through various distribution channels such as hospital and clinics, retail and specialty pharmacies and are used by various end users such as adult, geriatric.

What Is The Aimovig Market Growth Forecast?

The growth in the forecast period can be attributed to growth in chronic migraine diagnosis, expansion of insurance coverage, increased biologic drug acceptance, improved patient outcomes data, rising neurology specialist visits. Major trends in the forecast period include growing adoption of cgrp targeted therapies, rising focus on preventive migraine treatment, shift from acute to long term migraine management, increased use of biologic therapies, expansion of specialty pharmacy distribution.

Global Aimovig Market Segmentation

1) By Clinical Indication: Migraine, Cluster Headache, Other Headache Disorders 2) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies 3) By End User: Adult, Geriatric

What Are The Drivers Of The Aimovig Market?

The increasing incidence of migraine disorders is expected to propel the growth of the aimovig market going forward. Migraine, a complex neurological condition, is characterized by recurring headaches often accompanied by nausea, sensitivity to light and sound, and other symptoms. The rising incidence is due to several factors, including lifestyle changes, increasing stress levels, genetic predispositions, hormonal fluctuations (particularly in women), and greater diagnostic awareness. Aimovig, the first FDA-approved CGRP receptor blocker, is a leading treatment that addresses the unmet needs of migraine patients by offering a targeted, preventive solution. Aivimog is an innovative migraine management platform that uses advanced AI-driven algorithms to track, analyze, and predict migraine triggers, providing personalized recommendations for prevention, symptom relief, and real-time management through data-driven insights, ultimately helping migraine patients reduce the frequency, intensity, and duration of their attacks while improving their overall quality of life. For instance, in March 2024, according to the House of Commons Library, a UK-based government agency, approximately 10 million people live with migraine in the UK. Therefore, the increasing incidence of migraine disorders drives the aimovig industry. The rise in healthcare spending is expected to propel the growth of the aimovig market going forward. Healthcare spending refers to the total financial resources allocated by individuals, governments, private insurers, and other entities towards the provision of healthcare services and products. The rise in healthcare spending is attributed to aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. Healthcare spending supports Aimovig by driving investment in innovative treatments, expanding patient access through insurance coverage, funding ongoing research and development for improved therapeutic outcomes, and promoting public health initiatives that raise awareness and enhance the overall adoption of migraine prevention therapies. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, rise in healthcare spending is driving the growth of the aimovig industry. Rising personalized medicine is expected to propel the growth of the aimovig market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Aimovig, a monoclonal antibody designed to target and block the calcitonin gene-related peptide receptor, helps personalize medicine by providing an effective, tailored treatment for individuals suffering from chronic migraines, enabling healthcare providers to select the most appropriate therapy based on patient-specific factors, such as treatment history, efficacy, and tolerability, ultimately optimizing outcomes for each patient. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, rising personalized medicine drives the aimovig industry.

Key Players In The Global Aimovig Market

Major companies operating in the aimovig market are Novartis AG, Amgen Inc.

Regional Insights

North America was the largest region in the aimovig market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Aimovig Market?

The aimovig market consists of sales of monoclonal antibody-based therapies specifically developed to prevent migraines by inhibiting CGRP receptor activity. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Aimovig Market Report 2026?

The aimovig market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the aimovig industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.